WO2011155501A1 - 薬剤多量体微粒子及びその製造方法 - Google Patents

薬剤多量体微粒子及びその製造方法 Download PDF

Info

Publication number
WO2011155501A1
WO2011155501A1 PCT/JP2011/063084 JP2011063084W WO2011155501A1 WO 2011155501 A1 WO2011155501 A1 WO 2011155501A1 JP 2011063084 W JP2011063084 W JP 2011063084W WO 2011155501 A1 WO2011155501 A1 WO 2011155501A1
Authority
WO
WIPO (PCT)
Prior art keywords
general formula
drug
water
group
multimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2011/063084
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
笠井　均
中西　八郎
馬場　耕一
及川　英俊
村上　達也
博 今堀
充 橋田
勇 王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
Original Assignee
Japan Science and Technology Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science and Technology Agency filed Critical Japan Science and Technology Agency
Priority to EP11792458.9A priority Critical patent/EP2586463B1/en
Priority to JP2012519401A priority patent/JP5113958B2/ja
Priority to CN201180027818.7A priority patent/CN103068404B/zh
Priority to US13/702,205 priority patent/US20130096097A1/en
Publication of WO2011155501A1 publication Critical patent/WO2011155501A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to drug multimeric fine particles and a method for producing the same.
  • Organic fine particles are used in various fields because of their high chemical activity, unique electronic state, and good dispersion stability.
  • poorly soluble drugs are often used as aqueous suspension drugs in which fine drug particles are dispersed in water.
  • Aqueous suspension drugs exert their medicinal effects by gradually eluting fine particle drug components in the body. Therefore, in order to exert their medicinal effects efficiently, it is required that the particle diameter of the drug fine particles is as small as possible. .
  • organic pigments obtained by atomizing sparingly soluble organic dyes are used in many applications such as electrophotographic toners, inkjet inks, color filters, paints, and printing inks. These organic pigments are also required to have finer and more uniform fine particles from the viewpoint of improving various performances such as color reproducibility, image quality, and dispersion stability.
  • organic fine particles exhibit excellent performance by making them finer in various applications including these, technological development relating to nano-fine formation of organic compounds is being promoted.
  • a poorly soluble drug is often used as an aqueous suspension drug in which the drug is dispersed in water.
  • Aqueous suspension drugs have the property that fine drug components dispersed in water stay in the body, so they are effective to exert their effects locally or for a long time. Accordingly, it is used as an oral preparation, an external preparation for skin, an external preparation for nasal cavity, an external preparation for ophthalmology and the like.
  • An aqueous suspension drug is usually produced by dispersing a finely divided drug in water using a surfactant or the like.
  • the particle size of the drug obtained by pulverization is relatively large, and the variation in particle size is also large, so that large particle components settle due to long-term storage and rapid changes in the environment such as temperature.
  • the quality as an aqueous suspension drug is likely to vary, and even if the drug is manufactured by the same manufacturing method, the retention time is too short to be effective.
  • side effects may occur due to the time being too long. Therefore, there has been a demand for a method for obtaining fine drug particles having a small particle size and a narrow particle size distribution.
  • camptothecin which is an anticancer agent
  • specific derivatives thereof have been known (Patent Documents 1, 2, 3, 4 and 5).
  • Many camptothecins and their derivatives are very poorly soluble in water, limiting the clinical use of this drug.
  • Examples of water-soluble camptothecin derivatives include 9-dimethylaminomethyl-10-hydroxycamptothecin (Topotecan), 7-[(4-methylpiperazino) methyl] -10,11-ethylenedioxycamptothecin, 7-[(4-methylpiperazino ) Methyl] -10,11-methylenedioxycamptothecin, and 7-ethyl-10- [4- (1-piperidino) -1-piperidino] carbonyloxycamptothecin (CPT-11).
  • CPT-11 (Irinotecan / Camptosar®) was approved for use in humans by the US Food and Drug Administration in June 1996.
  • CPT-11 The active body of CPT-11 was found to be 10-hydroxy 7-ethylcamptothecin (SN-38) in 1984 in Miyasaka et al.
  • SN-38 has very poor water solubility and is not administered directly to human cancer patients.
  • SN-38 is further metabolized to form inactivated glucuronide species.
  • NK012 which is a polymer micelle preparation of SN-38, has been developed, but there are various problems with micellized nanoparticles, and its practical application is questionable.
  • Patent Document 7 a new method for producing a nanometer-scale fine particle dispersion called reprecipitation.
  • an organic material solution dissolved in a good solvent is injected into a poor solvent to produce a dispersion of ultrafine particles of the organic material.
  • this method it is possible to produce a fine particle dispersion of various substances.
  • an object of the present invention is to provide organic fine particles containing fine drug particles having a small particle size and a narrow particle size distribution, and a method for producing the same.
  • the present inventors have found that the above problems can be solved by using an organic compound having a plurality of the same main skeleton as the organic compound forming the fine particles as a crystal nucleating agent, and the present invention has been completed.
  • a plurality of drugs represented by the following general formula (1) are produced by dehydration condensation with each other a between molecules, and a plurality of the general formulas ( A drug obtained by injecting water into a solution obtained by dissolving a drug multimer in a water-miscible organic solvent, which is hydrolyzed to the drug represented by 1) Provide multimeric particulates.
  • A is a k-valent organic group, k is an integer of 2 or more, and a is a monovalent substituent.
  • the k a's may be the same or different. .
  • the second aspect of the present invention is characterized in that it is obtained by injecting into a water a solution in which a compound represented by the following general formula (3) is dissolved in a water-miscible organic solvent.
  • a compound represented by the following general formula (3) is dissolved in a water-miscible organic solvent.
  • drug multimer fine particles of the drug represented by (2) are provided.
  • A is a divalent organic group, and a and b are a hydroxyl group, an amino group, a carboxyl group, a thiol group, a hydrogen atom (however, on the secondary amine).
  • n is an integer of 1 or more
  • d is expressed by general formula (3) by hydrolysis of d in vivo.
  • the third aspect of the present invention is characterized in that it is obtained by injecting a solution in which a compound represented by the following general formula (5) is dissolved in water in a water-miscible organic solvent.
  • the present invention solves the above problems by providing drug multimer fine particles of the drug represented by (4).
  • A is a monovalent organic group.
  • a is a hydroxyl group, an amino group, a carboxyl group, a thiol group, a hydrogen atom
  • B is an m-valent substituent
  • d is d. Is hydrolyzed in vivo, whereby the compound represented by the general formula (5) is B (-f) m (f is a substituent selected from a hydroxyl group, an amino group, a carboxyl group, and a thiol group) A divalent substituent which is converted into a compound represented by.)
  • m drugs represented by the general formula (4) are examples of the general formula (4).
  • the compound represented by B (-f) m is succinic acid, fumaric acid, tartaric acid, malic acid, ascorbic acid, citric acid, lactic acid, amino acid, maleic acid, malonic acid, adipic acid, It is preferably any one of ethanolamine, trometamol, and glycerin.
  • d is preferably any group of —NHCO—, —CONH—, —COO—, and —OCOO—.
  • the fourth aspect of the present invention is a drug multimer obtained by injecting into a water a solution in which a compound represented by the following general formula (I) is dissolved in a water-miscible organic solvent. Provide fine particles.
  • D represents an anticancer agent
  • L represents an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted alkenyl, an optionally substituted alkynyl and an optionally substituted aryl.
  • D is preferably a camptothecin derivative
  • L is an optionally substituted alkyl or an optionally substituted alkenyl
  • D is SN-38
  • L is alkyl or alkenyl
  • R is —C ( ⁇ O) —, —C ( ⁇ O) NH— or alkylene.
  • the agent to be multiplied is preferably a poorly water-soluble agent having a solubility in water at 25 ° C. of 1.0 g / L or less.
  • a method for producing drug multimer fine particles characterized by being obtained by injecting a solution obtained by dissolving a drug multimer in a water-miscible organic solvent into water.
  • the body is formed by condensing a plurality of drugs represented by the following general formula (1) with each other a between molecules, and is converted into a drug represented by a plurality of general formulas (1) in vivo.
  • a method for producing drug multimer fine particles is provided.
  • A is a k-valent organic group, k is an integer of 2 or more, and a is a monovalent substituent.
  • the k a's may be the same or different. .
  • a water-miscible organic solvent prepared by injecting a solution prepared by dissolving a compound represented by the following general formula (5) into water.
  • A is a monovalent organic group.
  • a is a hydroxyl group, an amino group, a carboxyl group, a thiol group, a hydrogen atom
  • B is an m-valent substituent
  • d is d. Is hydrolyzed in vivo, whereby the compound represented by the general formula (5) is B (-f) m (f is a substituent selected from a hydroxyl group, an amino group, a carboxyl group, and a thiol group) A divalent substituent which is converted into a compound represented by.)
  • m drugs represented by the general formula (4) are examples of the general formula (4).
  • a compound represented by the following general formula (6) and a crystal nucleating agent that is a compound having a plurality of partial structures A included in the compound represented by the general formula (6) are added to an organic solvent.
  • the dissolved solution is obtained by injecting into a solvent which is a poor solvent for the compound represented by the general formula (6) and the crystal nucleating agent and is compatible with the organic solvent, In which the total amount of the partial structures A contained in the crystal nucleating agent is 0.0001 to 50 mol% with respect to the compound represented by the general formula (6).
  • a ′ is a k′-valent organic group
  • k ′ is an integer of 1 or more
  • a ′ is a hydrogen atom or a monovalent substituent.
  • K ′ a ′ In general formula (6), the number of atoms has a relationship of (number of atoms of partial structure A ′> number of atoms of other portion).
  • the total amount of the partial structure A is 0.0001 with respect to the compound represented by the following general formula (7) and the compound represented by the general formula (7) in the organic solvent.
  • a solution in which a compound represented by the following general formula (8) in an amount of ⁇ 50 mol% is dissolved is a poor solvent for the compounds represented by the general formula (7) and the general formula (8) and an organic solvent.
  • the object is to solve the above problems by providing organic fine particles of the compound represented by the general formula (7), which are obtained by injecting into a compatible solvent.
  • a ′ is a divalent organic group
  • a ′, b ′ and e ′ are each independently a hydrogen atom or a monovalent substituent
  • c ′ is hydrogen.
  • d ′ is a divalent linking group or a simple bond
  • m ′ is an integer of 1 or more
  • n ′ is an integer of 1 or more.
  • e ′, n ′, and m ′ ⁇ n ′ d's may be the same or different from each other, but all A's in the general formulas (7) and (8) have the same structure.
  • the number of atoms has a relationship of A ′> (a ′ + b ′).)
  • a ′ in the general formula (7) contains an aromatic and / or non-aromatic cyclic organic group, and a ′ and b ′ are an aromatic and / or non-aromatic cyclic organic group. It is preferable not to contain.
  • the compound represented by the general formula (8) is a compound represented by the following general formula (9).
  • a ′ and b ′ in the general formula (7) are each independently a monovalent substituent or a hydrogen atom having 1 to 3 atoms in the main chain excluding a hydrogen atom
  • D ′ in the general formula (8) or the general formula (9) is preferably a divalent linking group having 1 to 3 atoms in the main chain excluding a hydrogen atom or a simple bond.
  • a ′ and b ′ in the formula (7) are any of a carboxyl group, a hydroxyl group, an amino group, and a halogen atom.
  • the organic compound represented by the general formula (9) is formed by condensing the organic compound represented by the general formula (7) between each other in a ′ and b ′ between the molecules. It is also preferable that the polymer is a multimer of the organic compound represented by the formula:
  • a compound represented by the following general formula (6) and a crystal nucleating agent that is a compound having a plurality of partial structures A included in the compound represented by the general formula (6) are added to an organic solvent.
  • the dissolved solution is injected into a solvent that is a poor solvent for the compound represented by the general formula (6) and the crystal nucleating agent and is compatible with the organic solvent, and is represented by the general formula (6).
  • a method for producing organic fine particles of a compound wherein the crystal nucleating agent is an amount such that the total amount of the partial structures A possessed by the crystal nucleating agent is 0.0001 to 50 mol% with respect to the compound represented by the general formula (1)
  • a method for producing organic fine particles of a compound represented by the general formula (6) characterized in that the total number of atoms of all partial structures A in the crystal nucleating agent molecule is larger than the total number of atoms of other portions.
  • a ′ is a k′-valent organic group
  • k ′ is an integer of 1 or more
  • a ′ is a hydrogen atom or a monovalent substituent.
  • K ′ a ′ In general formula (6), the number of atoms has a relationship of (number of atoms of partial structure A ′> number of atoms of other portion).
  • the tenth aspect of the present invention is a drug multimer obtained by injecting into a water a solution in which a compound represented by the following general formula (I) is dissolved in a water-miscible organic solvent.
  • a method for producing fine particles is provided.
  • D represents an anticancer agent
  • L represents an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted alkenyl, an optionally substituted alkynyl and a substituted.
  • the eleventh aspect of the present invention provides the following drug dimer.
  • drug multimeric fine particles having a small particle size and a narrow particle size distribution can be easily obtained by utilizing a reprecipitation method established as a technique for producing ultrafine particles.
  • the reprecipitation method can be applied even to a drug having a structure in which fine particles cannot be easily obtained with a monomer.
  • This drug multimer is hydrolyzed in vivo to return to the original drug and substantially functions as drug fine particles themselves, so that drug efficacy and safety can be ensured.
  • organic fine particles having a sufficiently small particle size and a small particle size distribution can be provided.
  • the fine particles of the present invention can be produced using the reprecipitation method as they are, they can be obtained simply and at low cost.
  • fine particles having a sufficiently small particle diameter can be obtained even with a combination of an organic compound and a poor solvent that would increase the particle diameter in the conventional reprecipitation method.
  • FIG. 1 is a diagram showing the particle size of a dimer of SN38 and succinic acid.
  • FIG. 2 shows the particle size of the dimer of SN38 and tetramethylene diisocyanate.
  • FIG. 3 shows the anticancer activity of SN-38 dimer nanoparticles against HepG2.
  • FIG. 4 is a graph showing changes in anticancer activity against HepG2 when an aqueous dispersion of SN-38 dimer nanoparticles is aged.
  • FIG. 5 is a graph showing the influence of the binding mode used for the preparation of SN-38 dimer on the anticancer activity against HepG2.
  • the present invention is to obtain high-quality drug multimer fine particles by multimerizing a drug and applying a reprecipitation method.
  • a basic method for producing organic fine particles by a reprecipitation method is disclosed in Patent Document 1 described above, which can also be referred to.
  • the fine particles produced in the present invention are a multimer of a drug represented by the following general formula (1).
  • A is a k-valent organic group, which is a residue obtained by removing k substituents a from the drug represented by the general formula (1).
  • k is an integer of 2 or more, and a is a monovalent substituent.
  • the k a's may be the same as or different from each other.
  • the drug multimer used in the present invention is obtained by dehydrating and condensing a plurality of drugs represented by the general formula (1) at each other a between molecules.
  • the bond formed by this dehydration condensation is hydrolyzed in the living body by a change in pH or the action of an enzyme to return to the original two substituents a, and is then hydrolyzed into a plurality of drugs represented by the general formula (1). Disassembled.
  • the substituent represented by a is preferably a hydroxyl group, an amino group, a carboxyl group, a thiol group, a formyl group, a hydrogen atom (however, limited to a hydrogen atom on a secondary amine), particularly preferably a hydroxyl group, an amino group. It is preferably a group, a carboxyl group, or a hydrogen atom (however, a hydrogen atom on a secondary amine).
  • the bond formed by the condensation of two a's is preferably —NHCO—, —COO—, —OCOO—, —COS— or the like, and in particular, —NHCO— or —COO—. preferable.
  • k is an integer of 2 or more, and the upper limit is not particularly limited, but is usually 5 or less, preferably 3 or less, and particularly preferably 2, specifically, the following general formula ( A structure represented by 2) is preferred.
  • A is a divalent organic group
  • a and b are each a hydroxyl group, an amino group, a carboxyl group, a thiol group, and a hydrogen atom (however, limited to a hydrogen atom on a secondary amine).
  • the drug represented by the general formula (2) is made into a drug multimer having a structure represented by the following general formula (3) and is made into fine particles.
  • n is an integer greater than or equal to 1
  • d is general formula (3 by hydrolyzing d in the living body. ) Is a divalent substituent that is converted into n + 1 drugs represented by the general formula (2).
  • d is a substituent obtained by dehydrating and condensing the substituents a and b of the drug represented by the general formula (2) between the molecules, and d is usually —NHCO—, —COO—, — It is either OCOO- or -COS-, and among them, -NHCO- or -COO- is preferable.
  • n in the drug multimer represented by the general formula (3) is not particularly limited, but is usually 4 or less, preferably 2 or less, and particularly preferably 1.
  • the drug multimer may be linked to each other via a multifunctional compound.
  • the drug represented by the general formula (4) is made into a drug multimer having a structure represented by the following general formula (5) and is made into fine particles.
  • A is a monovalent organic group.
  • a is a substituent selected from a hydroxyl group, an amino group, a carboxyl group, a thiol group, and a hydrogen atom (but limited to a hydrogen atom on a secondary amine).
  • m is an integer of 2 or more
  • B is an m-valent substituent
  • d is a compound represented by the general formula (5) by hydrolysis of d in vivo.
  • d is a substituent obtained by dehydration condensation of the substituent a possessed by the drug represented by the general formula (4) and the substituent f possessed by the compound represented by B (-f) m.
  • it is one of —NHCO—, —CONH—, —COO—, —OCO—, —OCOO—, —COS—, —SCO—, among them —NHCO—, —CONH—, —COO—, — OCO- is preferred.
  • the upper limit of m in the drug multimer represented by the general formula (5) is not particularly limited, but is preferably usually 4 or less, preferably 3 or less, particularly preferably 2.
  • the compound represented by B (-f) m which is produced by hydrolysis of the drug multimer represented by the general formula (5) in vivo, is a compound that is safe for the living body. is necessary. Therefore, it is preferably a compound that is approved for administration to a living body. Specifically, it is preferably a compound having two or more substituents selected from a hydroxyl group, an amino group, a carboxyl group, and a thiol group described in the pharmaceutical additive dictionary.
  • Examples of such compounds include succinic acid, fumaric acid, maleic acid, tartaric acid, malic acid, ascorbic acid, citric acid, lactic acid, amino acids, malonic acid, adipic acid, triethanolamine, trometamol, glycerin and the like.
  • D in the general formula (I) represents an anticancer agent.
  • camptothecin and its derivatives for example, 10-hydroxycampothecin, 7-ethyl-10-hydroxycampothecin (SN-38), 9 -Aminocampothecin, etc. 7-ethyl-10-hydroxycampothecin (SN-38) is preferred.
  • L in the general formula (I) is an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted alkenyl, an optionally substituted alkynyl and an optionally substituted aryl. Is selected from the group Alkyl which may be substituted and alkenyl which may be substituted are preferred.
  • R1 represents hydrogen, alkyl, cycloalkyl which may be substituted or aryl which may be substituted, and hydrogen is preferable.
  • Alkyl refers to saturated aliphatic hydrocarbon groups, such as C1-C20 linear and branched groups.
  • the alkyl group is a medium size alkyl having 1 to 10 carbon atoms, such as methyl, ethyl, propyl, 2-propyl, n-butyl, iso-butyl, tert-butyl, pentyl, and the like. More preferably, the alkyl group is a lower alkyl having 1 to 4 carbon atoms, such as methyl, ethyl, propyl, 2-propyl, n-butyl, iso-butyl, or tert-butyl.
  • the alkyl group may be substituted or unsubstituted. When substituted, examples of the substituent include halo, hydroxyl, lower alkoxyl and the like.
  • Cycloalkyl refers to a 3- to 8-membered monocyclic ring consisting entirely of carbon, a 5 / 6-membered or 6-membered / 6-membered fused bicyclic ring consisting entirely of carbon, or multiple condensed A ring ("fused" ring system means that each ring of the system shares adjacent pairs of carbon atoms and other rings in the system), and one or more rings May contain one or more double bonds, but any of the rings refers to a multiple fused ring group that does not have a fully conjugated ⁇ -electron system.
  • cycloalkyl groups are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexadiene, adamantane, cycloheptane, cycloheptatriene and the like.
  • a cycloalkyl group may be substituted or unsubstituted. When substituted, examples of the substituent include lower alkyl, trihaloalkyl, halo, hydroxy, lower alkoxyl and the like.
  • Alkenyl refers to an alkyl group as defined above having at least two carbon atoms and at least one carbon-carbon double bond. Representative examples include ethenyl, 1-propenyl, 2-propenyl, 1-, 2-, 3-butenyl and the like, with ethenyl being preferred.
  • Alkynyl refers to an alkyl group as defined above having at least two carbon atoms and at least one carbon-carbon triple bond. Representative examples include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-, 2-, 3-butynyl and the like.
  • Aryl refers to a group having at least one aromatic ring, ie, a group having a conjugated ⁇ -electron system, for example, a cyclic aryl, heteroaryl and biaryl group consisting entirely of carbon.
  • the aryl group may be optionally substituted with one or more groups each independently selected from the group consisting of halo, trihalomethyl, hydroxy, SR, nitro, cyano, alkoxyl and alkyl.
  • Examples of the compound represented by the general formula (I) include However, it is not limited to these.
  • medical agent represented by General formula (1), General formula (2), General formula (4), and General formula (I) it is 25 degreeC from the characteristic of the reprecipitation method of injecting a solution in water and making it precipitate. It is preferably a poorly water-soluble drug having a solubility in water of 1.0 g / L or less, further 0.1 g / L or less, particularly 0.01 g / L or less.
  • drugs include anti-inflammatory agents, bronchodilators, antibiotics, antiviral agents, anti-HIV agents, immunosuppressants, immunostimulants, anesthetics, antifungal agents, antioxidants, antidiabetic agents, Hormones, vitamins, antidepressants, anticancer agents, muscle relaxants, stimulants, antitussives, labor control agents, anti-alcohol addiction agents, smoking cessation agents, antihypertensive agents, eye drops and the like are preferred.
  • the term “drug” refers to a drug specified in the Japanese Pharmacopoeia and / or Japanese Medicinal Medicine.
  • the drug multimer according to the present invention can be produced by methods known to those skilled in the art. For example, it can manufacture by dehydrating-condensing the chemical
  • the drug multimer having the structure represented by the general formula (5) can be produced by reacting the drugs represented by the general formula (4) with a polyfunctional compound.
  • the polyfunctional compound is preferably a compound having two or more substituents selected from, for example, a hydroxyl group, an amino group, a carboxyl group, a thiol group, a halogencarbonyl group, and an isocyanato group.
  • substituents selected from, for example, a hydroxyl group, an amino group, a carboxyl group, a thiol group, a halogencarbonyl group, and an isocyanato group.
  • the halogencarbonyl group include a chlorocarbonyl group and a bromocarbonyl group, and a chlorocarbonyl group is preferred.
  • the drug multimer represented by the general formula (I) is, for example, It can be produced based on the method described in US2007041093.
  • the drug multimer is first dissolved in an organic solvent which is a good solvent.
  • the organic solvent can be appropriately selected as long as it can dissolve the drug multimer and is miscible with water.
  • Specific examples of the organic solvent include, but are not limited to, acetone, tetrahydrofuran, dioxane, acetonitrile, methanol, ethanol, propanol, N-methylpyrrolidone, dimethyl sulfoxide, and the like. Or can be used in combination.
  • As the organic solvent acetone, ethanol, dimethyl sulfoxide and the like are preferable from the viewpoint of solubility and safety. *
  • the concentration of the drug multimer in the organic solvent is a major factor that affects the particle size of the fine particles to be generated, the concentration is appropriately changed according to the desired particle size.
  • the solution concentration is usually adjusted to about 0.1 to 15% by mass, but when the molecular weight is large, a solution of about 0.5% by mass is preferably adjusted.
  • an organic solvent solution of a drug multimer (hereinafter simply referred to as an organic solvent solution) is injected into water which is a poor solvent, drug multimer fine particles dispersed in water are generated.
  • the drug multimer since the drug multimer has a plurality of organic groups A, the solubility of the drug multimer in water is lower than that of the original drug. As a result, the drug multimer crystallizes more rapidly in water than the original drug, resulting in fine particles having a smaller particle size and particle size distribution.
  • the amount of water into which the organic solvent solution is injected is usually 10 times or more based on the volume of the drug multimer. There is no particular upper limit, but if there is too much water, the concentration of the drug multimer fine particles will become thin and it will be necessary to concentrate, so it is usually 100 times or less.
  • the particle size of the generated fine particles is controlled. be able to.
  • the temperature is controlled in the range of ⁇ 20 ° C. to 60 ° C. according to the desired particle size.
  • Injecting the organic solvent solution is preferably performed in a short time in agitated water in order to prevent variation in particle diameter.
  • an aqueous dispersion in which the crystallized or micronized drug multimer is uniformly dispersed in water can be obtained.
  • the obtained drug multimer fine particles can be used as an aqueous suspension drug in a state of being dispersed in water, or can be isolated as a fine particle powder by performing a solid-liquid separation operation such as filtration. .
  • an organic solvent added as a good solvent improves the safety of the drug.
  • Removed There is no restriction
  • drug multimer fine particles having a very small particle size and a narrow particle size distribution can be obtained.
  • By controlling the temperature of water, the type of good solvent, the amount added, etc. It is possible to produce drug multimer fine particles having a large particle size while maintaining a narrow particle size distribution.
  • drug multimers having an average particle size of about 50 nm to 10,000 nm are obtained by changing the production conditions. Fine particles can be produced.
  • the drug multimer is hydrolyzed into the original drug form in vivo due to the change in pH when passing through the living body and the action of enzymes such as esterase. Therefore, since it functions as a drug itself before being increased in vivo, the drug efficacy and safety of the drug multimer fine particles of the present invention can be ensured.
  • the organic fine particles produced in the present invention are fine particles of a compound represented by the following general formula (6).
  • a ′ is a k-valent organic group having an arbitrary carbon skeleton, k ′ is an integer of 1 or more, and a ′ is a hydrogen atom or a monovalent substituent.
  • the organic group A ′ is selected so as to be the main skeleton of the compound represented by the general formula (6).
  • the number of atoms in the general formula (6) has a relationship of (the number of atoms of the partial structure A ′> the number of atoms of other parts).
  • a ′ includes an aromatic and / or non-aromatic cyclic organic group, and a ′ represents an aromatic and / or non-aromatic cyclic organic group.
  • the compound represented by the general formula (6) is preferably selected from, for example, aromatic polycyclic compounds such as phthalocyanine, quinacridone, perylene, and indanthrene, and steroidal drugs.
  • aromatic polycyclic compounds such as phthalocyanine, quinacridone, perylene, and indanthrene
  • steroidal drugs Non-aromatic polycyclic compounds are exemplified.
  • Preferred substituents for a ′′ are monovalent substituents having 1 to 3 main chain atoms excluding hydrogen atoms, or hydrogen atoms, such as methyl, propyl, hydroxyl, and methoxy groups.
  • a carboxyl group, a hydroxyl group, and an amino group are preferable, and a carboxyl group, a hydroxyl group, an amino group, and a halogen atom are particularly preferable.
  • the “number of atoms in the main chain excluding hydrogen atoms” is the maximum number of atoms (excluding hydrogen) that can be counted in series from the atoms bonded to A ′.
  • the group is 3, the isopropyl group is 2, the acetyl group is 2, the carboxyl group is 2, the sulfo group is 2, the amino group is 1, and the halogen atom is 1.
  • k ′ is an integer of 1 or more, and the upper limit is not particularly limited, but is usually 5 or less, preferably 3 or less, and particularly preferably 2, specifically, the following general formula A structure represented by (7) is preferred.
  • a ′ is a divalent organic group having an arbitrary carbon skeleton, and a ′ and b ′ are each independently a hydrogen atom or a monovalent substituent.
  • the organic group A ′ is selected so as to be the main skeleton of the compound represented by the general formula (7). Specifically, the number of atoms of the partial structures A ′, a ′, and b ′ has a relationship of A ′> (a ′ + b ′).
  • a ′ includes an aromatic and / or non-aromatic cyclic organic group, and a ′ and b ′ are aromatic and / or non-aromatic cyclic.
  • aromatic polycyclic compounds such as phthalocyanine, quinacridone, perylene, and indanthrene
  • Non-aromatic polycyclic compounds such as
  • Preferred substituents for a ′ and b ′ include the same groups as a ′ in formula (6), and preferred groups are also the same.
  • the compound represented by the general formula (6) or the general formula (7) is dissolved in an organic solvent together with a crystal nucleating agent having a plurality of partial structures A included in the compound represented by the general formula (6) or the general formula (7). Is done.
  • the compound represented by the general formula (7) is dissolved in an organic solvent together with the compound represented by the following general formula (8).
  • A is an organic group having the same skeleton as A ′ in the general formula (7).
  • d ′ is a divalent linking group or a simple bond.
  • D ′ is simply a bond” means a state in which an organic group A ′ and an adjacent organic group A ′ are directly bonded without a substituent therebetween.
  • the divalent linking group is preferably a substituent having 1 to 3 atoms in the main chain excluding a hydrogen atom, and — (CH 2) x — (where x is 1 to 3 Represents an integer), —COO—, —CONH—, —COOCO—, —CON (R1) — (wherein R1 represents a hydrogen atom or a hydrocarbon group), —OCO—, —CH 2 OCO—, —O -, -S- and the like. More preferably, d ′ is any one of a simple bond, —OCO—, —COO—, —O—, —CONH—, and —COOCO—.
  • e ′ is a hydrogen atom or a monovalent substituent.
  • e ′ is particularly preferably a monovalent substituent having 1 to 3 atoms in the main chain excluding hydrogen atoms or a hydrogen atom.
  • n ′ is an integer of 1 or more
  • m ′ is an integer of 1 or more
  • m ′ is an integer of 1 or more
  • m ′ e ′, n ′ and m ′ ⁇ n ′ d ′ may be the same or different, but preferably m ′ n ′ and m ′ ⁇ n ′.
  • d ′ is the same number and structure, respectively.
  • n ′ is preferably 1 to 10, more preferably 1 or 2, and further preferably 1.
  • M ′ is preferably 1 to 4, and more preferably 1.
  • the compound represented by the general formula (8) may be a mixture of a plurality of types of compounds having a structure represented by the general formula (8).
  • c ′ is a hydrogen atom or an m′-valent substituent.
  • examples of c ′ include the same groups as a ′ in formula (6) when c ′ is a monovalent substituent, and the same as d ′ when c ′ is a divalent substituent. Examples are groups.
  • examples of the divalent or higher valent substituent include, for example, residues obtained by removing a hydrogen atom on the hydroxyl group of a polyhydric alcohol such as ethylene glycol, diethylene glycol, propylene glycol, glycerin, trimethylolpropane, diglycerin; oxalic acid, malon Acid, succinic acid, adipic acid, maleic acid, phthalic acid, hydroxyl group bonded to carbonyl of polyvalent carboxylic acid such as 1,3,5-benzenetricarboxylic acid or the residue after removing hydrogen atom on the hydroxyl group
  • a group a residue obtained by removing a hydrogen atom on an amino group from a polyvalent amine such as ethylenediamine, phenylenediamine, or 1,3,5-triaminobenzene; a compound having a plurality of halogen atoms such as dichlorobenzene or tribromobenzene Residues without halogen atom
  • Preferred examples of the compound represented by the general formula (8) include the “reactive substituent a ′ possessed by the compound represented by the general formula (7)” or the “compound represented by the general formula (7)”.
  • a compound in which a ′′ ′′ obtained by converting a substituent a ′ to a reactive substituent is reacted with a polyfunctional organic compound having the above-described residue and a plurality of such compounds are linked to the organic compound.
  • the compound represented by the general formula (8) is also preferably a compound represented by the following general formula (9).
  • c ′′ is a hydrogen atom or a monovalent substituent.
  • examples of c ′′ include the same groups as a ′ in general formula (6).
  • e ′ is particularly preferably a monovalent substituent having 1 to 3 atoms in the main chain excluding hydrogen atoms or a hydrogen atom.
  • p ′ is an integer of 1 or more.
  • the compound represented by the general formula (9) may be a mixture of a plurality of compounds having different values of p ′.
  • p ′ is preferably 1 to 10, more preferably 1 or 2, and even more preferably 1.
  • the number of atoms of the partial structures A ′, c ′′, and e ′ is preferably (p ′ + 1) A ′> (c ′′ + e ′ + p′d ′). Selected.
  • a ′ and b ′ which are reactive substituents of the compound represented by the general formula (7) are reacted and condensed between molecules, Converting a ′ and / or b ′ of the compound represented by the general formula (7) into a reactive group a ′′ and / or b ′′ with a compound represented by the general formula (7) And a plurality of organic groups A ′ linked by reacting a ′ or a ′′ with b ′ or b ′′ between molecules.
  • a compound represented by general formula (6) or general formula (7) (hereinafter collectively referred to as a compound represented by general formula (6)) and a crystal nucleating agent.
  • an organic solvent which is a good solvent.
  • the organic solvent can be appropriately selected as long as it can dissolve the compound represented by the general formula (6) and the crystal nucleating agent. Specific examples of the organic solvent depend on the compound to be dissolved and a poor solvent described later.
  • ketone solvents such as acetone and methyl ethyl ketone
  • cyclic ether solvents such as tetrahydrofuran and dioxane
  • nitrile solvents such as acetonitrile
  • methanol Alcohol solvents such as ethanol and isopropanol
  • polar amide solvents such as N, N-dimethylacetamide, N, N-dimethylformamide and N-methylpyrrolidone
  • sulfoxide solvents such as dimethyl sulfoxide and diethyl sulfoxide
  • phenol, o- , M-, or p-cresol xylenol, halogenated phenol, catechol and other phenolic solvents
  • aprotic polar solvents such as hexamethylphosphoramide and ⁇ -butyrolactone, etc. Or it may be mixed.
  • the concentration of the compound represented by the general formula (6) in the organic solvent is a large factor that affects the particle size of the generated fine particles, the concentration is appropriately changed according to the desired particle size.
  • the solution concentration is usually adjusted to about 0.1 to 15% by mass, but when the molecular weight is large, a solution of about 0.5% by mass is preferably adjusted.
  • the preferable addition amount of the crystal nucleating agent is such that the total amount of the partial structures A possessed by the crystal nucleating agent is 0.0001 to 50 mol% on the basis of the molar concentration of the compound represented by the general formula (6). Yes, preferably from 0.01 to 15 mol%.
  • the total amount of the partial structure A possessed by the crystal nucleating agent is a value obtained by multiplying the amount of the crystal nucleating agent by the number of the partial structures A contained in the crystal nucleating agent molecule. In the case of the compound represented by 8), it is a value obtained by multiplying the amount of the compound represented by the general formula (8) by (m ′ (n ′ + 1)).
  • the organic solvent solution of the compound represented by the general formula (6) and the crystal nucleating agent (hereinafter simply referred to as an organic solvent solution) is a poor solvent for the organic compound represented by the general formula (6) and the crystal nucleating agent, and It is injected into a solvent (hereinafter simply referred to as a poor solvent) that is compatible with the organic solvent used in the organic solvent solution.
  • a poor solvent the crystal nucleating agent precipitates earlier than the compound represented by the general formula (6) to form countless fine particles, and this is used as a crystal nucleus to crystallize the compound represented by the general formula (6). Done.
  • the crystallization of the compound represented by the general formula (6) is completed more quickly than when not using this, so the general formula ( Fine particles of the compound represented by 6) can be obtained. Since the obtained fine particles have a sufficiently small particle size, they can be obtained in a state stably dispersed in a poor solvent.
  • the poor solvent is a solvent in which the general formula (6) and the crystal nucleating agent can be precipitated when the organic solvent solution is added.
  • the poor solvent in addition to the solvents exemplified as the above organic solvents, water; aliphatic hydrocarbons such as hexane and heptane; alicyclic hydrocarbons such as decalin and cyclohexane; aromatics such as benzene, toluene and xylene Hydrocarbons; or a mixed solvent of two or more of these.
  • the poor solvent varies depending on the structure of the compound represented by the general formula (6), and is appropriately changed depending on the fine particles to be prepared and the purpose. For example, when it is desired to produce water-suspended fine particles of the compound represented by the general formula (6), water is used as the poor solvent.
  • a surfactant may be added in order to improve the dispersion stability of the obtained organic fine particles.
  • the amount thereof is not particularly limited, but if it is too much, it will adversely affect the formation of fine particles, so that it is usually used at about 0.1% by mass.
  • the amount of the poor solvent into which the organic solvent solution is injected is usually 10 times or more based on the volume of the organic solvent solution. Although there is no particular upper limit, it is preferable that the upper limit is not too large from the viewpoint of workability and economical efficiency of fine particle recovery. From the viewpoint of fine particle precipitation and workability, it is generally used about 100 times.
  • the poor solvent is preferably stirred in order to make the particle size of the generated organic fine particles uniform.
  • the stirring speed is not particularly limited, but is preferably 100 to 3000 rpm.
  • the temperature of the poor solvent at the time of injection is not particularly limited as long as the solvent remains in a liquid state, but the particle size also changes when the temperature of the poor solvent is changed, so by keeping the temperature of the poor solvent constant,
  • the particle diameter of the obtained organic fine particles can be controlled. For example, 5 When a poor solvent having a temperature lower than ° C. is used, the particle size of the organic fine particles tends to increase.
  • the temperature is controlled in the range of ⁇ 20 ° C. to 60 ° C. according to the desired particle size.
  • Injection is preferably performed in a short time at a time in order to prevent variation in the character of the particles.
  • a syringe is usually used.
  • fine particles having a particle size distribution of 50 to 10,000 nm and a small particle size distribution can be usually obtained in a state suspended in a poor solvent.
  • the particle size can be appropriately adjusted by controlling the temperature of the poor solvent, the type of crystal nucleating agent, the amount added, and the like.
  • the obtained organic fine particles can be used as a pigment ink, a suspending agent or the like in a suspended state, and can also be isolated as a powder by performing a solid-liquid separation operation such as filtration.
  • SN-38 (compound 18- (a)) (10 mg, 0.025 mmol) and 4-dimethylaminopyridine (DMAP: 7 mg, 0.058 mmol) were added to the two-necked eggplant-shaped flask. 1 ml of N-dimethylformamide (DMF) was added and stirred for 30 minutes. The eggplant-shaped flask was ice-cooled to 0 ° C., succinic dichloride (2.6 ⁇ l, 0.023 mmol) was added, and the mixture was stirred for 4 hours while gradually returning to room temperature.
  • DMF N-dimethylformamide
  • the stirred solution was transferred to a separatory funnel, ethyl acetate was added, and the mixture was washed twice or more with aqueous ammonium chloride.
  • the solution was divided into an aqueous phase and an organic phase, taken into an Erlenmeyer flask, the aqueous phase was confirmed by thin layer chromatography (TLC), and the organic phase was dehydrated with magnesium sulfate and filtered with cotton wool.
  • TLC thin layer chromatography
  • SN38 (20 mg, 0.051 mmol) was added to a two-necked eggplant-shaped flask, and the atmosphere was purged with nitrogen. Then, 0.3 ml of dehydrated DMF was added and stirred for 10 minutes to completely dissolve SN-38. 1,4-dibromo-2-butene (5.4 mg, 0.025 mmol) was added thereto and dissolved by stirring, and then 1.5 ml of dehydrated acetone and potassium carbonate (18 mg, 0.127 mmol) were added. Stirring was performed overnight. The stirred solution was transferred to a separatory funnel, charged with ethyl acetate, and washed several times with aqueous ammonium chloride.
  • the solution is divided into an aqueous phase and an organic phase, taken in an Erlenmeyer flask, the aqueous phase is confirmed by thin layer chromatography (TLC), the organic phase is dehydrated with magnesium sulfate, filtered with absorbent cotton, and then the filtrate is filtered.
  • TLC thin layer chromatography
  • the minimum amount of silica adsorbed on was added, and the solvent was completely distilled off under reduced pressure.
  • purified by the silica gel column chromatography which made the developing solvent chloroform / methanol 10/1.
  • the color of the purified crystals was pale yellow, and the yield of a dimer of SN-38 and 1,4-dibromo-2-butene (compound 18- (d)) was obtained at 23%.
  • Chloroform was added thereto to dissolve the product well, a minimum amount of silica adsorbed thereto was added, and the solvent was distilled off under reduced pressure. Further, the solution was drawn on a line, the solvent was completely removed, the silica was further dried until further purification, and the product was purified by silica gel chromatography using ethyl acetate as a developing solvent. The color of the purified crystal was white, and the yield of the dimer (compound 19- (b)) was 53%.
  • the dimer of SN-38 and tetramethylene diisocyanate was weighed to 5 mM and dissolved in 150 ⁇ l of DMSO.
  • a water dispersion of dimeric nanoparticles was prepared by injecting 100 ⁇ l of DMSO solution at room temperature into 10 ml of water with a poor solvent as water using a syringe. The final aqueous dispersion concentration was 0.05 mM.
  • the particle size was 50 nm ( Figure 2).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PCT/JP2011/063084 2010-06-11 2011-06-07 薬剤多量体微粒子及びその製造方法 Ceased WO2011155501A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP11792458.9A EP2586463B1 (en) 2010-06-11 2011-06-07 Pharmaceutical multimeric particles, and manufacturing method for same
JP2012519401A JP5113958B2 (ja) 2010-06-11 2011-06-07 薬剤多量体微粒子及びその製造方法
CN201180027818.7A CN103068404B (zh) 2010-06-11 2011-06-07 药物多聚物微粒及其制造方法
US13/702,205 US20130096097A1 (en) 2010-06-11 2011-06-07 Pharmaceutical multimeric particles, and manufacturing method for same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010-133486 2010-06-11
JP2010133486 2010-06-11

Publications (1)

Publication Number Publication Date
WO2011155501A1 true WO2011155501A1 (ja) 2011-12-15

Family

ID=45098106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/063084 Ceased WO2011155501A1 (ja) 2010-06-11 2011-06-07 薬剤多量体微粒子及びその製造方法

Country Status (5)

Country Link
US (1) US20130096097A1 (enExample)
EP (1) EP2586463B1 (enExample)
JP (2) JP5113958B2 (enExample)
CN (1) CN103068404B (enExample)
WO (1) WO2011155501A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150119388A1 (en) * 2012-06-15 2015-04-30 The Children's Hospital Philadelphia Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges
JPWO2022190626A1 (enExample) * 2021-03-12 2022-09-15
WO2024122113A1 (ja) * 2022-12-09 2024-06-13 国立研究開発法人科学技術振興機構 化合物、ナノ粒子、医薬、及びナノ粒子の製造方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020154815A1 (en) 2019-02-01 2020-08-06 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPH0679168A (ja) 1992-09-07 1994-03-22 Hitoshi Kasai 有機超微粒子の製法
WO1998035940A1 (en) 1997-02-14 1998-08-20 Bionumerik Pharmaceuticals, Inc. Highly lipophilic camptothecin derivatives
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US20070041093A1 (en) 2005-08-22 2007-02-22 Stuart Bard Projector screen for use in a lighted room
WO2007075825A2 (en) * 2005-12-20 2007-07-05 Sonus Pharmaceuticals, Inc. Lipophilic anticancer drug compounds
WO2008034124A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
WO2009013466A1 (en) * 2007-07-20 2009-01-29 Fujifilm Manufacturing Europe B.V. Preparation of fine particles
WO2009075391A1 (en) * 2007-12-13 2009-06-18 Kyushu University, National University Corporation Drug-containing nanoparticles
CN101628919A (zh) * 2009-08-20 2010-01-20 浙江大学 喜树碱及其衍生物的自乳化药物前体及其应用
WO2010053101A1 (ja) * 2008-11-06 2010-05-14 国立大学法人東北大学 眼内移行性の高い点眼剤および蛍光イメージング剤ならびにそれらの製造方法
US20100233190A1 (en) 2006-09-15 2010-09-16 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003253890A1 (en) * 2002-07-12 2004-02-02 Biomarin Pharmaceutical Inc. The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPH0679168A (ja) 1992-09-07 1994-03-22 Hitoshi Kasai 有機超微粒子の製法
WO1998035940A1 (en) 1997-02-14 1998-08-20 Bionumerik Pharmaceuticals, Inc. Highly lipophilic camptothecin derivatives
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US20070041093A1 (en) 2005-08-22 2007-02-22 Stuart Bard Projector screen for use in a lighted room
WO2007075825A2 (en) * 2005-12-20 2007-07-05 Sonus Pharmaceuticals, Inc. Lipophilic anticancer drug compounds
WO2008034124A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
US20100233190A1 (en) 2006-09-15 2010-09-16 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
WO2009013466A1 (en) * 2007-07-20 2009-01-29 Fujifilm Manufacturing Europe B.V. Preparation of fine particles
WO2009075391A1 (en) * 2007-12-13 2009-06-18 Kyushu University, National University Corporation Drug-containing nanoparticles
WO2010053101A1 (ja) * 2008-11-06 2010-05-14 国立大学法人東北大学 眼内移行性の高い点眼剤および蛍光イメージング剤ならびにそれらの製造方法
CN101628919A (zh) * 2009-08-20 2010-01-20 浙江大学 喜树碱及其衍生物的自乳化药物前体及其应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HITOSHI KASAI ET AL.: "Jisedai Yakuzai 'Pure Nano Drug' no Sosei to sorera no Yakuri Koka", 2010 NENDO DAI 10 KAI TAGEN BUSSHITSU KAGAKU KENKYUSHO KENKYU HAPPYOKAI KOEN YOKOSHU, 13 January 2011 (2011-01-13), pages 63 *
KEREN HABA ET AL.: "Single-Triggered Trimeric Prodrugs", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 44, 2005, pages 716 - 720, XP055069808, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/doi/10.1002/anie.200461657/abstract> *
MASAO SUZUKI ET AL.: "Preparation of Poly (amic acid) Nanoparticles Using the Reprecipitation Method and Their Imidization", JAPANESE JOURNAL OF POLYMER SCIENCE AND TECHNOLOGY, vol. 59, no. 10, 2002, pages 637 - 641, XP055100531 *
See also references of EP2586463A4
YOUQING SHEN ET AL.: "Prodrugs Forming High Drug Loading Multifunctional Nanocapsules for Intracellular Cancer Drug Delivery", JOURNAL OF AMERICAN CHEMICAL SOCIETY, vol. 132, no. 12, 10 March 2010 (2010-03-10), pages 4259 - 4265, XP055069801, Retrieved from the Internet <URL:http://pubs.acs.org/doi/abs/10.1021/ja909475m> *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150119388A1 (en) * 2012-06-15 2015-04-30 The Children's Hospital Philadelphia Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges
JPWO2022190626A1 (enExample) * 2021-03-12 2022-09-15
WO2022190626A1 (ja) * 2021-03-12 2022-09-15 国立大学法人東北大学 Ｓｎ－３８誘導体、当該誘導体を含むナノ粒子、医薬及び当該ナノ粒子の製造方法
JP7626491B2 (ja) 2021-03-12 2025-02-04 国立研究開発法人科学技術振興機構 Ｓｎ－３８誘導体、当該誘導体を含むナノ粒子、医薬及び当該ナノ粒子の製造方法
AU2022234045B2 (en) * 2021-03-12 2025-05-29 Japan Science And Technology Agency Sn-38 derivative, nano-particles containing said derivative, medicine, and method for producing said nano-particles
WO2024122113A1 (ja) * 2022-12-09 2024-06-13 国立研究開発法人科学技術振興機構 化合物、ナノ粒子、医薬、及びナノ粒子の製造方法

Also Published As

Publication number Publication date
EP2586463A1 (en) 2013-05-01
EP2586463A4 (en) 2014-03-19
EP2586463B1 (en) 2016-08-17
JPWO2011155501A1 (ja) 2013-08-01
CN103068404A (zh) 2013-04-24
CN103068404B (zh) 2015-11-25
JP5113958B2 (ja) 2013-01-09
US20130096097A1 (en) 2013-04-18
JP2013040189A (ja) 2013-02-28

Similar Documents

Publication Publication Date Title
JP5113958B2 (ja) 薬剤多量体微粒子及びその製造方法
WO2005118612A1 (en) Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs
CN109021026A (zh) 顺铂药物前体、制备方法和应用
CN114989182A (zh) 脂质化合物、包含其的组合物及应用
JP2019094260A (ja) 癌疾患治療用ナノ粒子化製剤
JP2021147340A (ja) 化合物、そのナノ粒子及び癌疾患の治療剤
AU2016265922B2 (en) A pharmaceutical co-crystal and use thereof
AU2022314101B2 (en) Cyclohexane lipidoids for nucleic acid transfection and use thereof
WO2016045505A1 (zh) 一种喜树碱类磷脂化合物、其药物组合物及应用
CN118724740A (zh) 氨基脂质、脂质纳米颗粒及其应用
CN104193779A (zh) 一种pH敏感磷脂药用材料及其制备方法与应用
WO2013067881A1 (zh) 水溶性维生素e衍生物修饰的双亲性抗癌药物化合物和制剂、该化合物的制备方法及应用
AU2008269148B2 (en) Crystalline polymorph of 7-ethyl-10-hydroxycamptothecin
US20180085344A1 (en) Method of use of diterpenoid derivatives as anticancer agents
ZA200604093B (en) Tocopherol-modified therapeutic drug compounds
CN118178664A (zh) 一种用于核酸递送的脂质材料及其用途
CN107001617B (zh) Peg衍生物
CN109044972A (zh) 共载紫杉醇的辣椒素前药聚合物胶束及其制备方法
CN112778370B (zh) 一种制备福奈妥匹坦的方法
CN102988293A (zh) 一种奥沙利铂叶酸靶向脂质体及其应用
CN116284006B (zh) 可电离脂质化合物、包含其的脂质载体及应用
CN113797195B (zh) 3-芳基香豆素类化合物的应用、抗癌增敏组合物及抗癌组合物
CN103772696B (zh) 一种羟基喜树碱的聚甘油脂肪酸酯衍生物
US20070148221A1 (en) Method of producing lipid complexed camptothecin-carboxylate
CN119613331B (zh) 3-羟基异烟酸右崁醇酯的季胺盐类化合物及其药物用途

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180027818.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11792458

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012519401

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 9715/CHENP/2012

Country of ref document: IN

REEP Request for entry into the european phase

Ref document number: 2011792458

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011792458

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13702205

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE